Clinical Report: Cognitive and Anti-Inflammatory Effects of NBM-DBS in Alzheimer's Disease

Overview

This open-label trial evaluated bilateral nucleus basalis of Meynert deep brain stimulation (NBM-DBS) in nine patients with moderate-to-severe Alzheimer's disease (AD). Results showed cognitive stabilization in moderate AD patients and significant immunomodulatory changes characterized by increased anti-inflammatory and decreased pro-inflammatory cytokines after 12 months.

Background

Alzheimer’s disease is a progressive neurodegenerative disorder marked by cognitive decline and functional impairment. The nucleus basalis of Meynert (NBM) provides cholinergic input critical for cognition and is severely affected in AD. Deep brain stimulation targeting the NBM (NBM-DBS) has emerged as a potential therapeutic approach, though clinical outcomes have been inconsistent. Chronic inflammation plays a key role in AD pathogenesis, and modulation of inflammatory pathways may underlie therapeutic effects.

Data Highlights

Key Findings

• NBM-DBS was well tolerated with no severe stimulation-related adverse events reported.
• Patients with moderate AD maintained cognitive function on MoCA and BNT over 12 months post-DBS.
• Patients with severe AD exhibited significant cognitive decline despite DBS treatment.
• Serum analysis revealed increased anti-inflammatory cytokines IL-10 and IL-27 at 12 months post-DBS.
• Pro-inflammatory chemokines CXCL10 and RANTES were significantly reduced after 12 months of stimulation.
• Therapeutic benefits of NBM-DBS appear more pronounced in moderate-stage AD, potentially via immunomodulation.

Clinical Implications

NBM-DBS may offer cognitive stabilization for patients with moderate Alzheimer’s disease, highlighting the importance of patient selection based on disease severity. The observed modulation of systemic inflammatory markers suggests that anti-inflammatory mechanisms could contribute to clinical benefits. These findings support further investigation of NBM-DBS as a targeted neuromodulatory therapy in moderate AD stages.

Conclusion

NBM-DBS shows promise in stabilizing cognition in moderate AD, potentially through anti-inflammatory effects. Future studies should focus on optimizing patient selection and elucidating mechanistic pathways to maximize therapeutic efficacy.

References

1. Kuhn et al. 2015 -- NBM-DBS effects on cognition and metabolism in AD
2. Beijing Tiantan Hospital Ethics Committee 2018 -- Study Protocol Approval
3. Invitrogen Bio-Plex200 Platform -- Cytokine and Chemokine Quantification